Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Short Interest Down 72.1% in October

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the recipient of a large decrease in short interest during the month of October. As of October 15th, there was short interest totaling 34,300 shares, a decrease of 72.1% from the September 30th total of 123,100 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average trading volume of 113,100 shares, the short-interest ratio is currently 0.3 days. Based on an average trading volume of 113,100 shares, the short-interest ratio is currently 0.3 days. Currently, 0.1% of the shares of the stock are sold short.

Barinthus Biotherapeutics Price Performance

Barinthus Biotherapeutics stock opened at $1.29 on Friday. Barinthus Biotherapeutics has a 12-month low of $0.64 and a 12-month high of $2.92. The stock has a market capitalization of $52.53 million, a P/E ratio of -0.75 and a beta of -0.71. The firm’s 50-day moving average is $1.26 and its two-hundred day moving average is $1.13.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.23). As a group, analysts forecast that Barinthus Biotherapeutics will post -1.38 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Barinthus Biotherapeutics in a research note on Tuesday, October 14th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $3.00.

Institutional Investors Weigh In On Barinthus Biotherapeutics

A hedge fund recently bought a new stake in Barinthus Biotherapeutics stock. HighTower Advisors LLC bought a new position in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 37,450 shares of the company’s stock, valued at approximately $36,000. HighTower Advisors LLC owned about 0.09% of Barinthus Biotherapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 25.20% of the company’s stock.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.